Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol.~* Filipino male or female subjects whose age at the first vaccination with Synflorix™ in this PMS should not be less than 6 weeks of age.~* Filipino male or female subjects who enter the PMS at the second dose should not be less than 10 weeks of age.~* Filipino male or female subjects who enter the PMS at the third dose should not be less than 14 weeks of age.~* Filipino male or female subjects who enter the PMS at the booster dose (i.e. if they have received Synflorix™ in the previous dose/s outside the PMS) should not be less than 10 months of age. The time interval between the primary vaccination and booster dose should be at least 6 months. For the booster dose, subjects who received PCV-7/-13 or Synflorix™ in their primary vaccination series will be allowed to take part in the PMS.~* Written and signed informed consent obtained from the parents/LAR(s) of the child. Where parents/LAR(s) are illiterate, the consent form will be countersigned by a witness.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Acute disease and/or fever at the time of vaccine administration.~* Fever is defined as temperature ≥ 37.5°C (99.5°F) on axillary, infrared or tympanic setting.~* Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* History of chronic condition(s) requiring treatment such as cancer or autoimmune diseases.~* Hypersensitivity to latex (found in syringe-tip cap and plunger).~* Any contraindications as stated in the Prescribing Information.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- Synflorix Group (Type: None): Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).